Short Interest Sector Focus: Technology Sector

As of the close of business on Friday, 9/2, we captured the Top 10 Highest Short Interest % stocks within the Technology Sector. The average short interest for stocks within the Technology sector stands at 3.37%. Therefore, the below stocks are showing a more pessimistic outlook than their peers within the respective sector.  

As of the close of business on Friday, 9/2, we captured the Top 10 Highest Short Interest % stocks within the Technology Sector.

The average short interest for stocks within the Technology sector stands at 3.37%. Therefore, the below stocks are showing a more pessimistic outlook than their peers within the respective sector.

 

  • AVAYA HOLDINGS COR    (NYSE:AVYA)    54.87%
  • MICROSTRATEGY        (NASDAQ:MSTR)    34.92%
  • RIOT BLOCKCHAIN IN    (NASDAQ:RIOT)    30.59%
  • DESKTOP METAL INC    (NYSE:DM)    28.52%
  • MICROVISION INC        (NASDAQ:MVIS)    26.45%
  • IROBOT CORP        (NASDAQ:IRBT)    22.56%
  • PAR TECHNOLOGY CP    (NYSE:PAR)    21.09%
  • AMERICAN VIRTUAL    (NASDAQ:AVCT)    20.98%
  • 8X8 INC NEW        (NYSE:EGHT)    20.86%
  • LUMINAR TECHNOLOGI    (NASDAQ:LAZR)    20.46%

Short Interest is the percentage of a stocks’ outstanding shares being sold short, which is utilized as a gauge for stock price sentiment. When short interest increases, this is generally considered a negative “bear” market indicator, whereas when short interest decreases, this is generally considered a positive “bull” market indicator. 

Disclaimer:
The Short Interest Indicator is produced by Tidal Markets, in partnership with Benzinga Insights. The data represented is exclusive to short interest data amalgamated daily by Tidal Markets LLC and its underlying proprietary sources. The information contained herein should not be compared to, contrasted, or evaluated against other short interest data providers. ANY INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE OR IMPLY INVESTMENT ADVICE
 

Total
0
Shares
Related Posts
Read More

Immutep to present final Overall Survival data from Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021

Immutep Limited (NASDAQ: IMMP) is pleased to announce it will report final Overall Survival (OS) data from its Phase IIb AIPAC clinical trial evaluating lead product candidate eftilagimod alpha ("efti" or "IMP321") in metastatic breast cancer at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021.

IMMP